Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Versant-built start-up finds targets, compounds for protein degradation via structural biology and proteomics

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives.

Launched from Versant Ventures’ Swiss incubator lab Ridgeline, Monte Rosa Therapeutics Inc. is also backed by New Enterprise Associates. On Tuesday, the company announced a $32.5 million series A round and a preclinical lead oncology candidate that degrades an undisclosed protein.

Monte Rosa is using structural biology and proteomics to

Read the full 768 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE